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Abstract 
Background: Stent-assisted coil embolization is effective for intracranial aneurysms, 
especially wide-necked aneurysms; however, the optimal antiplatelet regimens for 
ischemic events that develop after coil embolization have not yet been established. We 
aimed to determine the onset time of such postoperative ischemic events and the 
relationship between these events and antiplatelet therapy. 
Materials and Methods: We performed coil embolization using a vascular 
reconstruction stent for 43 cases of intracranial aneurysms and evaluated the incidence 
of postoperative ischemic events in these cases.  
Results: Nine patients showed postoperative ischemic events during the follow-up 
period (13 ± 7 months). Two patients developed cerebral infarction within 24 hours. 
Five patients developed transient ischemic attack within 40 days while they were 
receiving dual antiplatelet therapy. In addition, 1 patient showed cerebral infarction 143 
days postoperatively during single antiplatelet therapy, and a case of transient visual 
disturbance was reported 191 days postoperatively (49 days after antiplatelet therapy 
had been discontinued). We increased the number of antiplatelet agents in 4 of these 
patients. The other 5 patients were under strict observation with dual antiplatelet therapy. 
All of these patients were shifted to single antiplatelet therapy 3–13 months 
postoperatively. No recurrence of ischemic events was noted. 
Conclusion: Postoperative ischemic events are most likely to occur within 40 days 
postoperatively. For patients with postoperative ischemic events, additional ischemic 
events can be prevented by increasing the number of antiplatelet agents; subsequently, 
they can be shifted to single antiplatelet therapy after the risk of recurrence has 
decreased.  
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INTRODUCTION 
The use of intracranial stent-assisted coil embolization for treating intracranial 
aneurysms is associated with increased packing density and decreased coil deviation 
rates of the parent artery (1). Its use is effective for wide-necked aneurysms (2, 3). 
However, this procedure is also associated with the adverse complication of 
thromboembolic events. Previous studies have reported that adverse events occurred in 
25% of cases in which this procedure was performed, and ischemic events were 
specifically found in 4.5–22.2% of cases (4–7). In these earlier studies, 
two_ENREF_7_ENREF_6 antiplatelet agents were used for periods of 3 weeks to 6 
months after the operation, followed by administration of a single antiplatelet agent 
intended to be administered for the rest of the patients’ lives (4-7)_ENREF_8. However, 
administration of multiple antiplatelet agents has been reported to increase the risk of 
hemorrhagic events (8, 9)_ENREF_9_ENREF_9.  
Recently, a 5% risk of ischemic events was observed after a 6-week course of dual 
antiplatelet therapy (10). The optimal antiplatelet agent regimen for patients who have 
undergone intracranial stent-assisted coil embolization has not yet been established (10, 
11)_ENREF_11. In the present study, we examined the onset time of postoperative 
ischemic events following stent-assisted coil embolization and the relationship between 
these postoperative ischemic events and antiplatelet therapy. 
  
 
METHODS 
We retrospectively analyzed data from 96 patients with unruptured intracranial 
aneurysms at Fukuoka University Chikushi Hospital between July 2010 and May 2012. 
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Patients were included for data analysis if they were treated by coil embolization with 
an intracranial stent and if a follow-up assessment by a neurologist or neurosurgeon was 
performed at least 3 months after the operation. In Japan, the indications for using a 
CORDIS ENTERPRISE™ Vascular Reconstruction Device (Cordis Neurovascular, Inc., 
Miami, FL) include wide-necked intracranial aneurysms (diameter of aneurysmal neck 
> 4 mm or dome/neck ratio < 2) with a maximum aneurysmal dome diameter of 7 mm 
and a parent artery diameter between 2.5 and 4 mm. All patients gave their prior 
informed consent for participation in the study, which was approved by the ethics 
committee of Fukuoka University Chikushi Hospital. 
We used the techniques of standard multi projection cerebral angiography, 
three-dimensional (3D) digital subtraction angiography (DSA), magnetic resonance 
imaging (MRI), and time-of-flight magnetic resonance angiography (MRA) for 
preoperative evaluation measures. Morphologic evaluation and measurement of the 
aneurysm were done using reconstructed 3D DSA or MRA images. 
Our typical dual antiplatelet therapy before the operation was that patients received 
any 2 of the following 3 antiplatelet agents: aspirin (100 mg/day, first dose at least 3 
days before the operation), clopidogrel (75 mg/day, first dose at least 5 days before the 
operation) or cilostazol (200 mg/day, first dose at least 2 days before the operation). 
During the operation, patients were administered heparin at a dose that kept activated 
clotting times longer than 2–2.5 times their baseline values before insertion of the stent. 
Our typical protocol was to prescribe dual antiplatelet therapy for a period of 3–6 
months following the operation; subsequently, we prescribed single antiplatelet therapy 
after a postoperative investigation which included MRI and/or DSA. 
 We investigated the relationship between the onset of postprocedural ischemic events 
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and antiplatelet therapy. Postprocedural ischemic events primarily consisted of cases of 
cerebral infarction or transient ischemic attack (TIA); however, we also monitored 
ischemic eye symptoms as potential postoperative ischemic events if the intracranial 
stent was placed in the internal cerebral artery of the ipsilateral side. The event was 
defined as a cerebral infarction if the symptoms persisted for more than 24 hours and an 
abnormal new high intensity area (HIA) was detected by MRI examination with 
diffusion-weighted imaging (DWI-MRI). If the symptoms disappeared in less than 24 
hours and an abnormal new HIA was not detected by MRI-DWI or MRI examination 
with T2 weighted imaging (T2WI-MRI) after the ischemic event, it was defined as a 
TIA. In the case of ischemic eye symptoms, detailed examination including the eye 
ground was performed by ophthalmologists for confirmation. 
Fisher’s exact test was used to determine significant differences in gender, presence or 
absence of hypertension and ischemic heart disease, use of antiplatelet agents, and stent 
length between the group that experienced postoperative ischemic events and the group 
that did not. The Mann-Whitney U test was used for assessing all other parameters. P < 
0.05 was considered to indicate statistical significance.  
 
 
RESULTS 
Of the 96 patients treated in our department with endovascular procedures during a 
22-month period, 43 patients underwent coil embolization with an intracranial stent. 
These 43 patients comprised 11 men and 32 women with an average age of 60 ± 13 
years (mean ± SD). Of these 43 patients, 16 had hypertension, 2 had diabetes mellitus, 3 
had ischemic heart disease, 1 had chronic heart failure and 1 had left subclavian artery 
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occlusion. None of these 43 patients had a history of cerebral infarction before the 
operation. In all patients, an angiography performed immediately after coil embolization 
showed no signs of thromboembolic events. 
Two of the 43 cases discontinued antiplatelet therapy postoperatively. In 1 patient, 
antiplatelet therapy was discontinued due to apparent allergy to all 3 antiplatelet agents, 
a situation which was discovered on the 10th postoperative day. This patient was 
administered icosapentaenoic acid and did not experience an ischemic event. In the 
other patient, antiplatelet therapy was discontinued because of the patient’s low 
compliance with taking the drug. This patient experienced transient visual disturbance 
on the 191st postoperative day, 49 days after discontinuation of antiplatelet therapy.  
The follow-up period was 13 ± 7 months (mean ± SD; median: 14 months; range: 3–28 
months). During this period, 9 of the 43 patients experienced postoperative ischemic 
events. Of these 9 cases, 4 had hypertension but none showed other cardiovascular risk 
factors (for example, diabetes mellitus, arterial fibrillation, ischemic heart disease, 
chronic heart failure, or left subclavian artery occlusion). None of these 9 cases 
displayed evidence of in-stent stenosis or thrombosis on angiographic follow up.  
Although the latest event occurred on the 191st postoperative day, the median time of 
onset of postoperative events was 12 days. Two patients showed mild hemiparesis on 
the side opposite to the stented vessel within 24 hours after the operation, and these 
patients were diagnosed with cerebral infarction in the area of the stented vessel. Their 
symptoms were mild, and they were able to go home without assistance. Five patients 
were diagnosed as having experienced TIAs as evidenced by mild upper arm weakness 
on the side opposite to the stented vessel. Their symptoms occurred during the 40-day 
period after the operation during which they were receiving dual antiplatelet therapy. 
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One additional case of cerebral infarction in the area of the stented vessel occurred on 
the 143rd postoperative day, 36 days after the number of antiplatelet agents was reduced 
from 2 to 1. This patient experienced mild ataxia and returned home without assistance. 
A single case of transient decreased visual acuity caused by branch retinal artery 
occlusion occurred on the 191st postoperative day, 49 days after antiplatelet therapy had 
been discontinued. In this case, the stent was placed in the ipsilateral internal carotid 
artery (ICA), and the origin of the ophthalmic artery was included in the region of stent 
placement (Table 1). 
With respect to these 9 patients who developed postoperative ischemic events, we 
increased the number of antiplatelet agents in 4 cases, and in the other 5 cases, we kept 
the patients under strict observation with dual antiplatelet therapy. All the patients who 
experienced postoperative ischemic events were shifted to single antiplatelet therapy 
3–13 months postoperatively. Importantly, no additional ischemic events have been 
reported in these patients (Figure 1).  
We compared several indices between the group that experienced postoperative 
ischemic events (9 cases) and the remainder of the patient population that did not (34 
cases). Notably, postoperative ischemic events occurred only in women, suggesting a 
significant effect of gender. There was no statistically significant differences between 
these groups in other parameters, i.e. age, presence or absence of hypertension and 
ischemic heart disease, neck size of the aneurysm, dome size of the aneurysm, proximal 
diameter of the parent artery, distal diameter of the parent artery, operation time, 
antiplatelet agents, and stent length (Table 2). 
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DISCUSSION 
In this study, 77% of the postoperative ischemic events occurred within 40 days of the 
coil embolization under dual antiplatelet agents. One postoperative ischemic event 
occurred on the 143rd postoperative day under single antiplatelet therapy and another 
ischemic event occurred on the 191st postoperative day after discontinuation of 
antiplatelet therapy. All postoperative ischemic events occurred in the region of the 
stented vessel. Of the 9 cases in which postoperative ischemic events were observed, 4 
had hypertension but none displayed any other cardiovascular risk factors; therefore, the 
cause of these ischemic events is likely to be thrombosis. Previous reports have 
indicated the onset time of postoperative ischemic events to be during the 6-month 
postoperative period (5, 11–13). Kanaan et al. reported that thrombotic events and stent 
stenosis or occlusion were found in 9 of 133 cases. These events occurred within 35 
days of the operation in 6 of the 9 cases, and in 2 of the 6 cases, thrombotic events 
occurred 5 days after antiplatelet therapy had been reduced (5). Mocco et al. reported 
that delayed thrombotic events occurred in 3% of the cases, and these events were 
likewise associated with cessation of dual antiplatelet therapy (11). Rossen et al. 
reported that a 5% risk of ischemic events was found after a 6-week course of dual 
antiplatelet therapy (10). These results suggest that postoperative ischemic events are 
more likely to occur relatively soon after the operation and that the occurrence of 
postoperative ischemic events is directly influenced by antiplatelet therapy.  
 The anti-thrombotic property of stents is thought to be associated with neointima 
formation around the stent. The formation of neointima around the stent has been 
observed in animal experiments and angioscopic investigation of coronary arteries (14, 
15)_ENREF_16. Asakura et al. observed that the neointima became thicker up until 6 
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months after stenting and then became thin over a 3-year period as revealed by 
angioscopic investigation of coronary arteries. Moreover, luminal diameter was found 
to be decreased at 3–6 months, but increased at 3 years after stenting as shown by 
angiography (15). _ENREF_16Changes in luminal diameter were also found in 
intracranial stents for the treatment of intracranial aneurysm (16). This result suggests 
that neointimal remodeling develops around stents placed in cerebral arteries for the 
treatment of intracranial aneurysm in a similar manner as in stents implanted in 
coronary arteries for the treatment of atherosclerotic lesions.  
There is clearly good evidence that as neoendothelialization progresses, the 
thrombogenicity of intracranial stents decreases over a period of weeks to months. 
However, the optimal duration of dual antiplatelet therapy following intracranial stent 
insertion has not yet been determined (10). The results of the present study suggest that 
patients receiving stent-assisted coil embolization should be kept under strict 
observation for at least 40 days after their operation even if they are receiving dual 
antiplatelet therapy. Moreover, our finding that a single postoperative ischemic event 
occurred 143 days postoperatively while the patient was under single antiplatelet 
therapy provides a preliminary indication that dual antiplatelet therapy may be 
recommended for at least 5 months after the operation. The postoperative ischemic 
event that occurred 191 days postoperatively after antiplatelet therapy had been 
discontinued supports our conviction that single antiplatelet therapy should continue for 
more than 6 months after the procedure. Future ischemic events may be prevented by 
increasing the number of antiplatelet agents; the number of antiplatelet agents can be 
reduced later after the risk of recurrence of ischemic events has decreased. 
In this study, 2 cases of postoperative ischemic events were found within 24 hours 
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after the procedure. These could be described as periprocedural ischemic events or 
operative complications. However, it is difficult to differentiate between periprocedural 
and early-postoperative ischemic events. We believe that the risk of periprocedural 
ischemic events may be associated with the number of antiplatelet agents administered 
during the perioperative period. 
Based on our results, we would like to recommend the following revised antiplatelet 
agent regimen for intracranial stent-assisted coil embolization: triple antiplatelet therapy 
starting preoperatively until 6 weeks after the operation, followed by dual antiplatelet 
therapy up until 6 months postoperatively, and single antiplatelet therapy for the rest of 
the patient’s life. 
Obviously, an important consideration is that the administration of multiple antiplatelet 
agents increases the risk of hemorrhagic events_ENREF_9_ENREF_9. The incidence of 
life-threatening hemorrhagic events was reported to be higher with aspirin and 
clopidogrel than with clopidogrel alone and bleeding complications were observed over 
time (8). The annual incidence of life-threatening and major bleeding events was 
reportedly 1.21% with single antiplatelet agent administration and 2% with dual 
antiplatelet agent administration (9). We, therefore, plan to continue our efforts to 
determine the ideal timing and dosing for antiplatelet therapy following stent-assisted 
treatment of intracranial aneurysm. 
 
Limitations  
Antiplatelet function was not tested by a monitoring system such as the VerifyNow 
Assay (Accumetrics, San Diego, CA); consequently, the postoperative ischemic events 
observed in this study might have occurred due to low response to antiplatelet agents. In 
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previous studies, the incidence of aspirin resistance was 8–45% (17), and the proportion 
of non-responders and low responders to clopidogrel was 28–55% 
(18)_ENREF_20_ENREF_20_ENREF_20. These numbers indicate that resistance to 
antiplatelet agents should always be taken into consideration in the case of ischemic 
events. False positives might result from antiplatelet insensitivity in this study. However, 
the majority of the postoperative stroke events occurred during dual antiplatelet therapy, 
and there were no statistically significant differences between the combinations of 
antiplatelet agents used in this study.  
In this study, all the postoperative ischemic events occurred in women, resulting in a 
statistically significant difference for gender. Since we evaluated only 43 cases for 
postoperative ischemic events, it is quite possible that the statistical power of this study 
is insufficient to detect small differences.  
In order to circumvent these limitations, we plan to use larger patient populations and 
to include monitoring of antiplatelet function as we continue our investigations. 
 
CONCLUSION 
Postoperative ischemic events are most likely to occur within 40 days postoperatively 
even when patients were receiving dual antiplatelet agents. Our results indicate that 
when postoperative events occur, future ischemic events may be prevented by 
increasing the number of antiplatelet agents, and that the patients can be shifted to 
single antiplatelet therapy later after the risk of recurrent ischemic events has decreased. 
We aim to continue our investigations with our proposed antiplatelet agent regimen: 
triple antiplatelet therapy starting preoperatively until 6 weeks after the operation, 
followed by dual antiplatelet therapy until the 6-month postoperative time point, and 
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continuing single antiplatelet therapy throughout the patient’s life. We hope that these 
studies will help to optimize antiplatelet therapies for surgical patients at risk for 
ischemic events. 
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Figure Legend 
Figure 1. Onset time of postoperative ischemic events 
 
